开启时会模糊预览图，关闭后正常显示
(Human peers of course, the silicon members of your team will encourage you and praise you for your charming minimal level of understanding)
Opening portals to VR without headsets at @portalvr_io. Problems soluble, potential to improve invariant.
Haha, this is wild. I mean, a fine is just a tax with a gun. But I wasn't aware of the discrepancy. It would be smart to grow the income tax portion of the equation. But I have a feeling that legislative efforts focus much more on the fine part.
Building https://t.co/od97B0HVrk and https://t.co/666FnyVVE0 in Public. Raising all the boats with kindness. 🎙️ https://t.co/6w69DZmi8H · ✍️ https://t.co/lpnor5rsTW
“MoE models excel at world knowledge tasks but match dense models in reasoning when perplexity is fixed” Intuitively makes sense, but also, does it hold for more fine-grained MoEs? Reasoning is naturally sparse, you just combine a few low-rank operations.
We're in a race. It's not USA vs China but humans and AGIs vs ape power centralization. @deepseek_ai stan #1, 2023–Deep Time «C’est la guerre.» ®1
Your goal as an engineer used to be to maximally understand the code, and now the goal is to understand it as little as necessary. This, it turns out, is a much harder problem! Not just because it’s epistemologically more challenging, but because peers will ridicule you for it.
(Human peers of course, the silicon members of your team will encourage you and praise you for your charming minimal level of understanding)
RT @brentwpeterson: I just published DSPy: What ‘Programming Not Prompting’ Actually Means https://t.co/DJfVmKF9zc
Asst professor @MIT EECS & CSAIL (@nlp_mit). Author of https://t.co/VgyLxl0oa1 and https://t.co/ZZaSzaRaZ7 (@DSPyOSS). Prev: CS PhD @StanfordNLP. Research @Databricks.
One of the most profound and unsolved supply-demand mismatch problems in healthcare is the too wide chasm between the incredible, one-and-done "miracle drugs", which have the potential to entirely cure diseases that would otherwise be debilitating or fatal, and the actual patients who struggle to gain access to those therapies in a sustainable and affordable way. At the core, this is an incentive problem, an infrastructure problem, and a clinical operations problem that requires a comprehensive, sophisticated, multi-player solution. In that vein - we're thrilled to have backed Aradigm from inception, and to finally launch and announce their Series A, led by our friends at Frist Cressey Ventures, and including our friends at @MorganHealth. Our very own Dr. William Shrank and Annie Collins, along with Spencer Carrucciu, were born to build this company. Let's go Team Aradigm - in the name of creating an efficient marketplace for these amazing therapeutic innovations! @a16zBioHealth @a16z @JayRughani @JorgeCondeBio
https://t.co/aU89UyR37e
